BJDX
Bluejay Diagnostics, Inc.
Medical - Devices
Market Cap$334K
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BJDX vs OSUR
Revenue, margins, valuation, and 5-year total return — side by side.
OSUR
OraSure Technologies, Inc.
Medical - Instruments & Supplies
Market Cap$225M
5Y Perf.-66.5%
BJDX vs OSUR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BJDX | OSUR |
|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $334K | $225M |
| Revenue (TTM) | $0.00 | $85M |
| Net Income (TTM) | $-7M | $-53M |
| Gross Margin | — | 38.8% |
| Operating Margin | — | -58.6% |
| Total Debt | $222K | $13M |
| Cash & Equiv. | $4M | $199K |
BJDX vs OSUR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BJDX
OSUR
| Stock | Nov 21 | May 26 | Return |
|---|---|---|---|
| Bluejay Diagnostics… (BJDX) | 100 | 0.0 | -100.0% |
| OraSure Technologie… (OSUR) | 100 | 33.5 | -66.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BJDX vs OSUR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BJDX leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. OraSure Technologies, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
BJDX
Bluejay Diagnostics, Inc.
The Income Pick
BJDX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.89
- EPS growth 42.1%
- Lower volatility, beta 0.89, Low D/E 3.9%, current ratio 6.05x
Best for: income & stability and growth exposure
OSUR
OraSure Technologies, Inc.
The Long-Run Compounder
OSUR is the clearest fit if your priority is long-term compounding.
- -53.1% 10Y total return vs BJDX's -100.0%
- +12.2% vs BJDX's -73.5%
- -12.8% ROA vs BJDX's -140.1%, ROIC -20.0% vs -399.9%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BJDX | 19.8% revenue growth vs OSUR's -38.1% |
| Quality / Margins | BJDX | -10.2% margin vs OSUR's -61.9% |
| Stability / Safety | BJDX | Beta 0.89 vs OSUR's 1.45 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | OSUR | +12.2% vs BJDX's -73.5% |
| Efficiency (ROA) | OSUR | -12.8% ROA vs BJDX's -140.1%, ROIC -20.0% vs -399.9% |
BJDX vs OSUR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
BJDX vs OSUR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLOSURLAGGINGBJDX
BJDXBluejay Diagnostics, …
1leads
OSUROraSure Technologies,…
3leads
6 Total Categories
CATEGORYLEADERvs BJDXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BJDX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
OSUR6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
OSUR6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
OSUR1/1
Income & Cash Flow (Last 12 Months)
BJDX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
OSUR and BJDX operate at a comparable scale, with $85M and $0 in trailing revenue.
| Metric | BJDXBluejay Diagnosti… | OSUROraSure Technolog… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $85M |
| EBITDAEarnings before interest/tax | -$7M | -$45M |
| Net IncomeAfter-tax profit | -$7M | -$53M |
| Free Cash FlowCash after capex | -$6M | -$33M |
| Gross MarginGross profit ÷ Revenue | — | +38.8% |
| Operating MarginEBIT ÷ Revenue | — | -58.6% |
| Net MarginNet income ÷ Revenue | — | -61.9% |
| FCF MarginFCF ÷ Revenue | — | -38.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -99.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +89.1% | -52.4% |
BJDX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — BJDX and OSUR each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | BJDXBluejay Diagnosti… | OSUROraSure Technolog… |
|---|---|---|
| Market CapShares × price | $333,773 | $225M |
| Enterprise ValueMkt cap + debt − cash | -$4M | $238M |
| Trailing P/EPrice ÷ TTM EPS | -0.04x | -3.33x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 1.96x |
| Price / BookPrice ÷ Book value/share | 0.06x | 0.67x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — BJDX and OSUR each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
OSUR leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
OSUR delivers a -15.1% return on equity — every $100 of shareholder capital generates $-15 in annual profit, vs $-186 for BJDX. OSUR carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to BJDX's 0.04x. On the Piotroski fundamental quality scale (0–9), OSUR scores 3/9 vs BJDX's 2/9, reflecting mixed financial health.
| Metric | BJDXBluejay Diagnosti… | OSUROraSure Technolog… |
|---|---|---|
| ROE (TTM)Return on equity | -185.5% | -15.1% |
| ROA (TTM)Return on assets | -140.1% | -12.8% |
| ROICReturn on invested capital | -4.0% | -20.0% |
| ROCEReturn on capital employed | -160.3% | -16.8% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 |
| Debt / EquityFinancial leverage | 0.04x | 0.04x |
| Net DebtTotal debt minus cash | -$4M | $13M |
| Cash & Equiv.Liquid assets | $4M | $199,278 |
| Total DebtShort + long-term debt | $222,249 | $13M |
| Interest CoverageEBIT ÷ Interest expense | -5972.19x | — |
OSUR leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
OSUR leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in OSUR five years ago would be worth $3,174 today (with dividends reinvested), compared to $0 for BJDX. Over the past 12 months, OSUR leads with a +12.2% total return vs BJDX's -73.5%. The 3-year compound annual growth rate (CAGR) favors OSUR at -23.5% vs BJDX's -94.4% — a key indicator of consistent wealth creation.
| Metric | BJDXBluejay Diagnosti… | OSUROraSure Technolog… |
|---|---|---|
| YTD ReturnYear-to-date | -30.5% | +31.5% |
| 1-Year ReturnPast 12 months | -73.5% | +12.2% |
| 3-Year ReturnCumulative with dividends | -100.0% | -55.2% |
| 5-Year ReturnCumulative with dividends | -100.0% | -68.3% |
| 10-Year ReturnCumulative with dividends | -100.0% | -53.1% |
| CAGR (3Y)Annualised 3-year return | -94.4% | -23.5% |
OSUR leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BJDX and OSUR each lead in 1 of 2 comparable metrics.
Risk & Volatility
BJDX is the less volatile stock with a 0.89 beta — it tends to amplify market swings less than OSUR's 1.45 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OSUR currently trades 81.9% from its 52-week high vs BJDX's 10.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BJDXBluejay Diagnosti… | OSUROraSure Technolog… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.89x | 1.45x |
| 52-Week HighHighest price in past year | $16.68 | $3.82 |
| 52-Week LowLowest price in past year | $0.78 | $2.08 |
| % of 52W HighCurrent price vs 52-week peak | +10.9% | +81.9% |
| RSI (14)Momentum oscillator 0–100 | 46.8 | 47.1 |
| Avg Volume (50D)Average daily shares traded | 26K | 473K |
Evenly matched — BJDX and OSUR each lead in 1 of 2 comparable metrics.
Analyst Outlook
OSUR leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
| Metric | BJDXBluejay Diagnosti… | OSUROraSure Technolog… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $4.00 |
| # AnalystsCovering analysts | — | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 2 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +6.7% |
OSUR leads this category, winning 1 of 1 comparable metric.
Key Takeaway
OSUR leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). BJDX leads in 1 (Income & Cash Flow). 2 tied.
Best OverallOraSure Technologies, Inc. (OSUR)Leads 3 of 6 categories
Loading custom metrics...
BJDX vs OSUR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BJDX or OSUR a better buy right now?
Analysts rate OraSure Technologies, Inc.
(OSUR) a "Hold" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BJDX or OSUR?
Over the past 5 years, OraSure Technologies, Inc.
(OSUR) delivered a total return of -68. 3%, compared to -100. 0% for Bluejay Diagnostics, Inc. (BJDX). Over 10 years, the gap is even starker: OSUR returned -53. 1% versus BJDX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BJDX or OSUR?
By beta (market sensitivity over 5 years), Bluejay Diagnostics, Inc.
(BJDX) is the lower-risk stock at 0. 89β versus OraSure Technologies, Inc. 's 1. 45β — meaning OSUR is approximately 62% more volatile than BJDX relative to the S&P 500. On balance sheet safety, OraSure Technologies, Inc. (OSUR) carries a lower debt/equity ratio of 4% versus 4% for Bluejay Diagnostics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — BJDX or OSUR?
On earnings-per-share growth, the picture is similar: Bluejay Diagnostics, Inc.
grew EPS 42. 1% year-over-year, compared to -261. 5% for OraSure Technologies, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BJDX or OSUR?
Bluejay Diagnostics, Inc.
(BJDX) is the more profitable company, earning 0. 0% net margin versus -59. 8% for OraSure Technologies, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BJDX leads at 0. 0% versus -59. 2% for OSUR. At the gross margin level — before operating expenses — OSUR leads at 41. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BJDX or OSUR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BJDX or OSUR better for a retirement portfolio?
For long-horizon retirement investors, Bluejay Diagnostics, Inc.
(BJDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 89)). Both have compounded well over 10 years (BJDX: -100. 0%, OSUR: -53. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BJDX and OSUR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.